In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
-
An overview on rare disease research
ICON's Tim Clark and Will Maier examine the key clinical, regulatory, and commercial challenges associated with the development of therapies for the treatment of rare diseases.
-
The potential of activity trackers to bias study results
A thought leadership article authored by Marie McCarthy, Tim Clark and Peter Schueler on the impact of activity trackers on study participants and study endpoints.
-
A conversation with an expert in drug development
Colin Orford, Senior Vice President of Drug Development services at ICON, about finding an effective treatment for COVID-19.
-
Use of televisits in studies and related PV concerns
As a result of the COVID-19 pandemic, televisits are becoming strongly considered as an alternative to on-site face-to-face visits, and as a new approach in virtual decentralised trials. ICON’s Xavier Fournie, a member of the EUCROF Pharmacovigilance Working Group, discusses the potential impact of televisits on pharmacovigilance (PV) processes. As a result of the COVID-19 pandemic, televisits are becoming strongly considered as an alternative to on-site face-to-face visits, and as a new approach in virtual decentralised trials. ICON’s Xavier Fournie, a member of the EUCROF Pharmacovigilance Working Group, discusses the potential impact of televisits on pharmacovigilance (PV) processes.
-
Encouraging patient participation in real world studies
Real world data is rapidly becoming the latest frontier for life sciences companies for supporting regulatory filings and conducting drug safety surveillance. ICON experts discuss the critical role of patients and advocacy groups in the June issue of Pharmaceutical Market Europe.
-
Virtual Congresses – Facing up to virtual reality
The COVID-19 pandemic has challenged the traditional onsite congress engagement experience and forced pharma to rethink face to face events.
-
Going through changes
ICON's Angela Brown considers what manufacturers can learn from medical device regulation (MDR) and the effect it will have on the in vitro diagnostic landscape (IVD)
-
Challenges and opportunities in harnessing the potential of circulating tumor cells
Scientific Affairs Manager Candice Willey provides commentary on the difficulties of using CTCs in diagnostic testing despite their promise, the emergence of new CTC technologies to improve tumor sample accessibility, and the benefits of integrating CTC information into clinical trial decisions.
-
The importance of partnering for bioanalytical studies
BioPharm International speaks with ICON's Robert Kernstock about the need for bioanalytical testing programs and regulatory strategies for potential new biologics.
